X-55009249-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4BP6
The NM_000032.5(ALAS2):c.1695G>C(p.Glu565Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: not found (cov: 23)
Consequence
ALAS2
NM_000032.5 missense
NM_000032.5 missense
Scores
1
3
13
Clinical Significance
Conservation
PhyloP100: 0.779
Genes affected
ALAS2 (HGNC:397): (5'-aminolevulinate synthase 2) The product of this gene specifies an erythroid-specific mitochondrially located enzyme. The encoded protein catalyzes the first step in the heme biosynthetic pathway. Defects in this gene cause X-linked pyridoxine-responsive sideroblastic anemia. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.26509172).
BP6
Variant X-55009249-C-G is Benign according to our data. Variant chrX-55009249-C-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 2634710.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=1}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ALAS2 | NM_000032.5 | c.1695G>C | p.Glu565Asp | missense_variant | 11/11 | ENST00000650242.1 | NP_000023.2 | |
ALAS2 | NM_001037968.4 | c.1656G>C | p.Glu552Asp | missense_variant | 11/11 | NP_001033057.1 | ||
ALAS2 | NM_001037967.4 | c.1584G>C | p.Glu528Asp | missense_variant | 10/10 | NP_001033056.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALAS2 | ENST00000650242.1 | c.1695G>C | p.Glu565Asp | missense_variant | 11/11 | NM_000032.5 | ENSP00000497236 | P1 | ||
ALAS2 | ENST00000396198.7 | c.1656G>C | p.Glu552Asp | missense_variant | 11/11 | 5 | ENSP00000379501 | |||
ALAS2 | ENST00000335854.8 | c.1584G>C | p.Glu528Asp | missense_variant | 10/10 | 2 | ENSP00000337131 | |||
ALAS2 | ENST00000498636.1 | c.824G>C | p.Ser275Thr | missense_variant | 5/5 | 3 | ENSP00000495662 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD3 genomes
Cov.:
23
GnomAD3 exomes AF: 0.00000585 AC: 1AN: 170826Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 57204
GnomAD3 exomes
AF:
AC:
1
AN:
170826
Hom.:
AF XY:
AC XY:
0
AN XY:
57204
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 23
GnomAD4 genome
Cov.:
23
Bravo
AF:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
ALAS2-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 20, 2023 | The ALAS2 c.1695G>C variant is predicted to result in the amino acid substitution p.Glu565Asp. To our knowledge, this variant has not been reported in patients with ALAS2-related disorder. However, in a functional analysis, this variant was found to result in a small gain of function in enzymatic activity (Tchaikovskii et al. 2019. PubMed ID: 30678654). This variant is reported in 0.0081% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/X-55035682-C-G). Of note, a different variant impacting the same amino acid residue (p.Glu565Lys) has been reported in a patient with sideroblastic anemia onset in the third decade of life (Liu et al. 2013. PubMed ID: 24323989). At this time, the clinical significance of the c.1695G>C (p.Glu565Asp) variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 15, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
.;T;T;.
FATHMM_MKL
Benign
D
LIST_S2
Benign
T;.;T;T
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Uncertain
T
MutationAssessor
Benign
.;N;N;.
MutationTaster
Benign
D;D;D
PrimateAI
Benign
T
PROVEAN
Benign
N;.;N;N
REVEL
Uncertain
Sift
Benign
T;.;T;T
Sift4G
Benign
T;.;T;T
Polyphen
0.0010
.;B;B;.
Vest4
MutPred
0.50
.;Gain of relative solvent accessibility (P = 0.0479);Gain of relative solvent accessibility (P = 0.0479);.;
MVP
MPC
0.45
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at